Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind study of risankizumab versus ustekinumab in adults with moderate to severe Crohn's disease after anti-TNF failure
MOH_2020-10-01_009344Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Sep 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of risankizumab and ustekinumab in Crohn's disease (3 arms), sponsored by AbbVie Inc. Primary endpoint: Change in Crohn's Disease Activity Index. Started Sep 2020; status: active, not recruiting.
02
Drugs
risankizumabustekinumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on MOH_2020-10-01_009344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-10-01_009344.